Caratterizzazione di marcatori immunofenotipici in metastasi polmonari da osteosarcoma

Title

Code

MetOS

Type

Sperimentale

Start Year

2024

Status

In Corso

Principal Investigator

051-6366566; Fax: 051-6366974

nicola.baldini@ior.it

Baldini Nicola, MD

Director

Biomedical Science and Technologies and Nanobiotechnology Lab

Operational unit that carry out the study

complex unit

Scienze e tecnologie biomediche e nanobiotecnologie

Director

Baldini Nicola, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. MetOS

Thursday 21 November 2024, 16:10

PG0016572_2024_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

Sito Web Istituto Ortopedico Rizzoli

DIPARTIMENTO RIZZOLI-SICILIA

Caratterizzazione di marcatori immunofenotipici in metastasi polmonari da osteosarcoma

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in